Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Inclisiran→

Inclisiran Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1639324-58-5
Molecular formula
C529H681F12N176O316P43S6
Molecular weight
17284.72 g/mol
Drug class
Small interfering RNA (siRNA) targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA
Mechanism of action
A GalNAc-conjugated double-stranded siRNA is taken up by hepatocytes and directs RNA-induced silencing complex (RISC)-mediated degradation of PCSK9 mRNA, reducing hepatic PCSK9 protein and increasing LDL-receptor recycling and LDL-cholesterol clearance.
Indications / reported uses
  • Adjunct to diet and exercise to reduce LDL-cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and clinical atherosclerotic cardiovascular disease, under the applicable product label

Sources: US DailyMed — LEQVIO (inclisiran) · EMA EPAR — Leqvio · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Small interfering RNA (siRNA) targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA

Mechanism of action

A GalNAc-conjugated double-stranded siRNA is taken up by hepatocytes and directs RNA-induced silencing complex (RISC)-mediated degradation of PCSK9 mRNA, reducing hepatic PCSK9 protein and increasing LDL-receptor recycling and LDL-cholesterol clearance.

General use cases

  • Adjunct to diet and exercise to reduce LDL-cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and clinical atherosclerotic cardiovascular disease, under the applicable product label

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Inclisiran Environmental Risk Assessment (ERA) (the Inclisiran ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.